Is IMTX or DYN more profitable?

Dyne Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immatics -495.71% -47.41% -39.45% Dyne Therapeutics N/A -64.30% -50.33%

Does the media refer more to IMTX or DYN?

In the previous week, Immatics had 3 more articles in the media than Dyne Therapeutics. MarketBeat recorded 12 mentions for Immatics and 9 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.58 beat Immatics' score of 0.92 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to EWTX or IMTX?

In the previous week, Immatics had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 12 mentions for Immatics and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat Immatics' score of 0.92 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immatics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation & earnings, IMTX or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than Immatics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immatics $41.70M 30.38 -$222.26M -$1.86 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Does the media refer more to IMTX or PBLS?

In the previous week, Immatics had 2 more articles in the media than Parabilis Medicines. MarketBeat recorded 12 mentions for Immatics and 10 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 1.31 beat Immatics' score of 0.92 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Parabilis Medicines 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CELC or IMTX more profitable?

Celcuity has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Immatics -495.71% -47.41% -39.45%

Does the media refer more to CELC or IMTX?

In the previous week, Immatics had 2 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for Immatics and 10 mentions for Celcuity. Celcuity's average media sentiment score of 1.20 beat Immatics' score of 0.92 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor IMTX or RLAY?

In the previous week, Relay Therapeutics had 7 more articles in the media than Immatics. MarketBeat recorded 19 mentions for Relay Therapeutics and 12 mentions for Immatics. Relay Therapeutics' average media sentiment score of 1.09 beat Immatics' score of 0.92 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Relay Therapeutics 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immatics (IMTX) Competitors

$9.45 +0.09 (+0.96%)

As of 08/28/2026 04:00 PM Eastern

Compare

IMTX vs. DYN, EWTX, PBLS, CELC, and RLAY

Should you buy Immatics stock or one of its competitors? Immatics's main competitors and comparable companies include Dyne Therapeutics (DYN), Edgewise Therapeutics (EWTX), Parabilis Medicines (PBLS), Celcuity (CELC), and Relay Therapeutics (RLAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immatics compare to Dyne Therapeutics?

Immatics (NASDAQ:IMTX) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Dyne Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
Dyne Therapeutics	N/A	-64.30%	-50.33%

Immatics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$41.70M	30.38	-$222.26M	-$1.86	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Immatics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Immatics currently has a consensus target price of $20.60, indicating a potential upside of 117.99%. Dyne Therapeutics has a consensus target price of $34.42, indicating a potential upside of 37.28%. Given Immatics' higher probable upside, analysts clearly believe Immatics is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

64.4% of Immatics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 3.3% of Immatics shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Immatics had 3 more articles in the media than Dyne Therapeutics. MarketBeat recorded 12 mentions for Immatics and 9 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.58 beat Immatics' score of 0.92 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Immatics beats Dyne Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Immatics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Immatics (NASDAQ:IMTX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

In the previous week, Immatics had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 12 mentions for Immatics and 10 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.59 beat Immatics' score of 0.92 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immatics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Edgewise Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Immatics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

Edgewise Therapeutics has higher earnings, but lower revenue than Immatics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Immatics	$41.70M	30.38	-$222.26M	-$1.86	N/A

Edgewise Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Edgewise Therapeutics' return on equity of -39.01% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Immatics	-495.71%	-47.41%	-39.45%

Edgewise Therapeutics currently has a consensus price target of $50.33, indicating a potential upside of 17.71%. Immatics has a consensus price target of $20.60, indicating a potential upside of 117.99%. Given Immatics' higher possible upside, analysts plainly believe Immatics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

64.4% of Immatics shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Edgewise Therapeutics beats Immatics on 10 of the 16 factors compared between the two stocks.

How does Immatics compare to Parabilis Medicines?

Immatics (NASDAQ:IMTX) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Immatics presently has a consensus price target of $20.60, suggesting a potential upside of 117.99%. Parabilis Medicines has a consensus price target of $41.67, suggesting a potential upside of 6.54%. Given Immatics' higher possible upside, analysts plainly believe Immatics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

64.4% of Immatics shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Immatics had 2 more articles in the media than Parabilis Medicines. MarketBeat recorded 12 mentions for Immatics and 10 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 1.31 beat Immatics' score of 0.92 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Parabilis Medicines	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Parabilis Medicines has lower revenue, but higher earnings than Immatics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$41.70M	30.38	-$222.26M	-$1.86	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Parabilis Medicines has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Parabilis Medicines' return on equity of 0.00% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
Parabilis Medicines	N/A	N/A	N/A

Summary

Immatics and Parabilis Medicines tied by winning 6 of the 12 factors compared between the two stocks.

How does Immatics compare to Celcuity?

Celcuity (NASDAQ:CELC) and Immatics (NASDAQ:IMTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

63.3% of Celcuity shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 13.3% of Celcuity shares are held by insiders. Comparatively, 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Celcuity has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Immatics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

In the previous week, Immatics had 2 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for Immatics and 10 mentions for Celcuity. Celcuity's average media sentiment score of 1.20 beat Immatics' score of 0.92 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Celcuity presently has a consensus target price of $154.55, indicating a potential upside of 74.75%. Immatics has a consensus target price of $20.60, indicating a potential upside of 117.99%. Given Immatics' higher possible upside, analysts plainly believe Immatics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Celcuity has higher earnings, but lower revenue than Immatics. Celcuity is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Immatics	$41.70M	30.38	-$222.26M	-$1.86	N/A

Celcuity has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Immatics	-495.71%	-47.41%	-39.45%

Summary

Immatics beats Celcuity on 9 of the 15 factors compared between the two stocks.

How does Immatics compare to Relay Therapeutics?

Immatics (NASDAQ:IMTX) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Immatics currently has a consensus price target of $20.60, indicating a potential upside of 117.99%. Relay Therapeutics has a consensus price target of $25.92, indicating a potential upside of 38.07%. Given Immatics' higher probable upside, equities research analysts clearly believe Immatics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Immatics has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$41.70M	30.38	-$222.26M	-$1.86	N/A
Relay Therapeutics	$10.35M	397.42	-$276.48M	-$1.57	N/A

Relay Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Relay Therapeutics' return on equity of -42.27% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
Relay Therapeutics	N/A	-42.27%	-38.67%

Immatics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

64.4% of Immatics shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 3.3% of Immatics shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Relay Therapeutics had 7 more articles in the media than Immatics. MarketBeat recorded 19 mentions for Relay Therapeutics and 12 mentions for Immatics. Relay Therapeutics' average media sentiment score of 1.09 beat Immatics' score of 0.92 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Relay Therapeutics	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relay Therapeutics beats Immatics on 13 of the 17 factors compared between the two stocks.

Get Immatics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMTX vs. The Competition

Export

Metric	Immatics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.27B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-5.08	11.62	273.16	25.45
Price / Sales	30.38	1,295.89	605.01	76.63
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	2.72	16.53	12.98	6.14
Net Income	-$222.26M	-$22.80M	$3.48B	$348.86M
7 Day Performance	5.82%	-0.31%	0.13%	-0.80%
1 Month Performance	2.72%	9.80%	7.08%	4.13%
1 Year Performance	85.66%	55.66%	24.67%	15.17%

Immatics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMTX Immatics	2.875 of 5 stars	$9.45 +1.0%	$20.60 +118.0%	+85.7%	$1.27B	$41.70M	N/A	260	News Coverage Analyst Forecast Insider Trade Gap Up High Trading Volume
DYN Dyne Therapeutics	3.7073 of 5 stars	$26.00 -0.6%	$34.42 +32.4%	+85.8%	$4.86B	N/A	N/A	100	Positive News
EWTX Edgewise Therapeutics	3.3248 of 5 stars	$44.11 +0.2%	$49.08 +11.3%	+198.0%	$4.79B	N/A	N/A	60	News Coverage Positive News
PBLS Parabilis Medicines	2.7311 of 5 stars	$39.35 +5.7%	$41.67 +5.9%	N/A	$4.65B	$148K	N/A	N/A	News Coverage
CELC Celcuity	2.7597 of 5 stars	$93.24 +0.9%	$154.55 +65.8%	+72.6%	$4.55B	N/A	N/A	40	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMTX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immatics (IMTX) Competitors

IMTX vs. DYN, EWTX, PBLS, CELC, and RLAY

How does Immatics compare to Dyne Therapeutics?

Summary

How does Immatics compare to Edgewise Therapeutics?

Summary

How does Immatics compare to Parabilis Medicines?

Summary

How does Immatics compare to Celcuity?

Summary

How does Immatics compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immatics (IMTX) Competitors

IMTX vs. DYN, EWTX, PBLS, CELC, and RLAY

How does Immatics compare to Dyne Therapeutics?

Is IMTX or DYN more profitable?

Which has preferable earnings and valuation, IMTX or DYN?

Which has more volatility & risk, IMTX or DYN?

Do analysts prefer IMTX or DYN?

Do insiders and institutionals believe in IMTX or DYN?

Does the media refer more to IMTX or DYN?

Summary

How does Immatics compare to Edgewise Therapeutics?

Does the media refer more to EWTX or IMTX?

Which has more risk & volatility, EWTX or IMTX?

Which has higher earnings & valuation, EWTX or IMTX?

Is EWTX or IMTX more profitable?

Do analysts prefer EWTX or IMTX?

Do institutionals and insiders believe in EWTX or IMTX?

Summary

How does Immatics compare to Parabilis Medicines?

Do analysts recommend IMTX or PBLS?

Do insiders & institutionals have more ownership in IMTX or PBLS?

Does the media refer more to IMTX or PBLS?

Which has better valuation & earnings, IMTX or PBLS?

Is IMTX or PBLS more profitable?

Summary

How does Immatics compare to Celcuity?

Do insiders and institutionals believe in CELC or IMTX?

Which has more risk and volatility, CELC or IMTX?

Does the media refer more to CELC or IMTX?

Do analysts recommend CELC or IMTX?

Which has stronger valuation & earnings, CELC or IMTX?

Is CELC or IMTX more profitable?

Summary

How does Immatics compare to Relay Therapeutics?

Do analysts prefer IMTX or RLAY?

Which has stronger earnings and valuation, IMTX or RLAY?

Is IMTX or RLAY more profitable?

Which has more risk & volatility, IMTX or RLAY?

Do insiders & institutionals hold more shares of IMTX or RLAY?

Does the media favor IMTX or RLAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools